Developer docs
API playgroundTry for free, no card

Search company profiles

onconcept®

Full company profile

uuid02mk6mi

Namestring
onconcept®
Legal namestring
ONConcept®
Company typeenum
Private
Founded yearint
2019
Descriptiontext

ONConcept® is a strategic partnership formed in 2019 by three independent, certified European pharmaceutical companies — Bluepharma (Portugal), Helm AG (Germany), and Welding GmbH & Co. KG (Germany) — to develop, manufacture, and supply complex, highly potent pharmaceutical products, principally generic oncology drugs and other difficult-to-make therapeutics. The partnership operates a dedicated EU-GMP manufacturing site in Eiras, Coimbra, Portugal, purpose-built for oral solid high-potency dosage forms with a €30 million capital investment and approximately 100 highly qualified staff, with the site successfully inspected by the USFDA on six occasions and by multiple other national regulatory authorities.

The portfolio comprises more than 20 generic molecules including blockbusters such as ibrutinib, palbociclib, cabozantinib, nilotinib, olaparib, and enzalutamide, spanning oncology, hematology, immunology, and antivirals. ONConcept pairs these assets with proprietary formulation work — notably a nanoenzalutamide tablet developed with Nanoform — and offers an end-to-end service stack covering IP support, API sourcing, FDF development and manufacturing, clinical development, and regulatory support. The company targets the wave of patent expirations (2020–2024) affecting highly potent anticancer molecules with annual sales exceeding $26 billion, with planned launches including Nilotinib in 2026 and nanoenzalutamide potentially as early as 2028.

Commercially, ONConcept serves multinational and local pharmaceutical companies through long-term, multi-molecule strategic alliances rather than one-off product licenses, leveraging the complementary strengths of its three founding partners (Bluepharma's CDMO capabilities and EU-GMP manufacturing, Helm's scientific and regulatory expertise with 120+ years of corporate history, and Welding's API sourcing and project leadership) to position itself as an integrated European hub serving global markets including the US, South America, and Asia-Pacific.

Short descriptiontext

ONConcept® is a strategic partnership of Bluepharma, Helm AG, and Welding that develops, manufactures, and licenses complex, highly potent generic pharmaceuticals — primarily oncology drugs — through long-term multi-molecule alliances with global pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersCoimbra, Portugal
HQ citystring
Coimbra
HQ countrystring
Portugal
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
high potency pharmaceuticals, oncology drug development, pharmaceutical CDMO services, generic oncology products, pharmaceutical licensing
Industry4 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Generic Oncology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Licensing
TypeLicensing Royalties
Description

Licensing of developed generic pharmaceutical products (highly potent molecules) to marketing partners worldwide. Products include oncology drugs and other complex therapeutics at various stages of regulatory approval.

onconceptpharma.com
2Contract Development and Manufacturing (CDMO)
TypeProfessional Services
Description

Bluepharma operates as a CDMO with full capabilities to develop medicines from concept through commercial manufacturing. Services include FDF development, manufacturing, supply chain management, clinical development, regulatory support, and IP services.

onconceptpharma.com
3Product Supply
TypeTransaction Fee
Description

Supply of manufactured highly potent pharmaceutical products to pharmaceutical companies under long-term strategic alliances.

onconceptpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ONConcept® is a strategic partnership that develops, manufactures, and licenses generic versions of oncology and other highly potent pharmaceutical products (oral solid dosage forms) for marketing partners worldwide. The partnership operates a €30 million EU-GMP approved manufacturing facility in Portugal and provides integrated CDMO services across the full pharmaceutical value chain, including IP support, API sourcing, FDF development/manufacturing/supply chain, clinical development, and regulatory support for more than 20 molecules.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Portfolio of 20+ molecules including top sellers like ibrutinib (Imbruvica®) and palbociclib (Ibrance®)
+2 more records
Product overview1 text field

ONConcept® is a strategic partnership among three European pharmaceutical companies (Bluepharma, Helm Pharma, and Welding) providing integrated CDMO services for complex, differentiated, and highly potent pharmaceutical products. The portfolio consists of 20+ generic pharmaceutical products including oral solid dosages (tablets and capsules) spanning oncology (abiraterone acetate,apalutamide, cabozantinib, enzalutamide, lenvatinib, nilotinib, olaparib, palbociclib, pazopanib, pomalidomide, ribociclib, ruxolitinib, sunitinib, venetoclax), hematology (eltrombopag, avatrombopag), immunology (fingolimod, tofacitinib standard and extended-release), with partner Nanoform for nano-formulation technology. The services span the full value chain: IP support, API sourcing, FDF development and manufacturing, clinical development, and regulatory support. EU-based manufacturing facility in Portugal with GMP certifications.

Product and service6 records
1Abiraterone Acetate
CategoryGeneric Pharmaceutical Product
Description

Generic version of Zytiga® (250mg, 500mg tablets) for the treatment of prostate cancer, supplied for licensing and distribution to pharmaceutical partners.

2Apalutamide
CategoryGeneric Pharmaceutical Product
Description

Generic version of Erleada® (60mg, 240mg tablets) for the treatment of prostate cancer, supplied for licensing and distribution to pharmaceutical partners.

3Avatrombopag
CategoryGeneric Pharmaceutical Product
Description

Generic version of Doptelet® (20mg tablets) for the treatment of thrombocytopenia, supplied for licensing and distribution to pharmaceutical partners.

4Cabozantinib
CategoryGeneric Pharmaceutical Product
Description

Generic version of Cabometyx® (20mg, 40mg, 60mg tablets) for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer, supplied for licensing and distribution to pharmaceutical partners.

5Eltrombopag
CategoryGeneric Pharmaceutical Product
Description

Generic version of Revolade®/Promacta® (25/50/75 mg tablets) for thrombocytopenia and severe aplastic anemia, supplied for licensing and distribution to pharmaceutical partners.

6Enzalutamide
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bluepharma is a Portuguese pharmaceutical company operating as a CDMO with all capabilities needed to develop medicines from concept through commercial manufacturing. Bluepharma brings EU-GMP approved manufacturing capabilities, global regulatory experience, and the manufacturing facility base for ONConcept. As a founding partner, Bluepharma provides development expertise, regulatory filing capabilities, and the production infrastructure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Helm is a family-owned, 120-year-old German pharmaceutical company with strong track record collaborating with international partners on generic pharmaceutical development. Helm brings scientific, regulatory, and quality expertise, experience coordinating different stakeholders, and special expertise in identifying opportunities for difficult and complex molecules. As a founding partner, Helm handles active pharmaceutical ingredient (API) expertise and regulatory coordination.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Welding is a German pharmaceutical company based in Hamburg, with history dating back to 1955 involved in API supply. Welding brings expertise in identifying and handling ingredients, connecting API suppliers to finished dosage form manufacturers. The company has excellent reputation for leading projects from start to finish, with experience in markets including India, China, and the US. As a founding partner, Welding provides API sourcing network and project leadership.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

onconcept®

Generic Oncology Pharmaceuticalsonconceptpharma.com

ONConcept® is a strategic partnership of Bluepharma, Helm AG, and Welding that develops, manufactures, and licenses complex, highly potent generic pharmaceuticals — primarily oncology drugs — through long-term multi-molecule alliances with global pharmaceutical companies.

What onconcept® does

ONConcept® is a strategic partnership formed in 2019 by three independent, certified European pharmaceutical companies — Bluepharma (Portugal), Helm AG (Germany), and Welding GmbH & Co. KG (Germany) — to develop, manufacture, and supply complex, highly potent pharmaceutical products, principally generic oncology drugs and other difficult-to-make therapeutics. The partnership operates a dedicated EU-GMP manufacturing site in Eiras, Coimbra, Portugal, purpose-built for oral solid high-potency dosage forms with a €30 million capital investment and approximately 100 highly qualified staff, with the site successfully inspected by the USFDA on six occasions and by multiple other national regulatory authorities.

The portfolio comprises more than 20 generic molecules including blockbusters such as ibrutinib, palbociclib, cabozantinib, nilotinib, olaparib, and enzalutamide, spanning oncology, hematology, immunology, and antivirals. ONConcept pairs these assets with proprietary formulation work — notably a nanoenzalutamide tablet developed with Nanoform — and offers an end-to-end service stack covering IP support, API sourcing, FDF development and manufacturing, clinical development, and regulatory support. The company targets the wave of patent expirations (2020–2024) affecting highly potent anticancer molecules with annual sales exceeding $26 billion, with planned launches including Nilotinib in 2026 and nanoenzalutamide potentially as early as 2028.

Commercially, ONConcept serves multinational and local pharmaceutical companies through long-term, multi-molecule strategic alliances rather than one-off product licenses, leveraging the complementary strengths of its three founding partners (Bluepharma's CDMO capabilities and EU-GMP manufacturing, Helm's scientific and regulatory expertise with 120+ years of corporate history, and Welding's API sourcing and project leadership) to position itself as an integrated European hub serving global markets including the US, South America, and Asia-Pacific.

onconcept® firmographics

Firmographics
Name
onconcept®
Legal name
ONConcept®
Website
https://onconceptpharma.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
501–1,000 employees
Short description
ONConcept® is a strategic partnership of Bluepharma, Helm AG, and Welding that develops, manufactures, and licenses complex, highly potent generic pharmaceuticals — primarily oncology drugs — through long-term multi-molecule alliances with global pharmaceutical companies.
Ownership category
akta.pro rank

onconcept® industry classification

Industry
Product category
Generic Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • High potency pharmaceuticals
  • Oncology drug development
  • Pharmaceutical CDMO services
  • Generic oncology products
  • Pharmaceutical licensing

Where onconcept® is headquartered

Location

Headquarters

HQ city
Coimbra
HQ country
Portugal
HQ region
Europe

Offices4 records

Markets served

onconcept® business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing: Licensing of developed generic pharmaceutical products (highly potent molecules) to marketing partners worldwide. Products include oncology drugs and other complex therapeutics at various stages of regulatory approval.
  2. Contract Development and Manufacturing (CDMO): Bluepharma operates as a CDMO with full capabilities to develop medicines from concept through commercial manufacturing. Services include FDF development, manufacturing, supply chain management, clinical development, regulatory support, and IP services.
  3. Product Supply: Supply of manufactured highly potent pharmaceutical products to pharmaceutical companies under long-term strategic alliances.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

onconcept® product offering

Product offering

Core offering

ONConcept® is a strategic partnership that develops, manufactures, and licenses generic versions of oncology and other highly potent pharmaceutical products (oral solid dosage forms) for marketing partners worldwide. The partnership operates a €30 million EU-GMP approved manufacturing facility in Portugal and provides integrated CDMO services across the full pharmaceutical value chain, including IP support, API sourcing, FDF development/manufacturing/supply chain, clinical development, and regulatory support for more than 20 molecules.

Product overview

ONConcept® is a strategic partnership among three European pharmaceutical companies (Bluepharma, Helm Pharma, and Welding) providing integrated CDMO services for complex, differentiated, and highly potent pharmaceutical products. The portfolio consists of 20+ generic pharmaceutical products including oral solid dosages (tablets and capsules) spanning oncology (abiraterone acetate,apalutamide, cabozantinib, enzalutamide, lenvatinib, nilotinib, olaparib, palbociclib, pazopanib, pomalidomide, ribociclib, ruxolitinib, sunitinib, venetoclax), hematology (eltrombopag, avatrombopag), immunology (fingolimod, tofacitinib standard and extended-release), with partner Nanoform for nano-formulation technology. The services span the full value chain: IP support, API sourcing, FDF development and manufacturing, clinical development, and regulatory support. EU-based manufacturing facility in Portugal with GMP certifications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Abiraterone Acetate Generic version of Zytiga® (250mg, 500mg tablets) for the treatment of prostate cancer, supplied for licensing and distribution to pharmaceutical partners.
  • Apalutamide Generic version of Erleada® (60mg, 240mg tablets) for the treatment of prostate cancer, supplied for licensing and distribution to pharmaceutical partners.
  • Avatrombopag Generic version of Doptelet® (20mg tablets) for the treatment of thrombocytopenia, supplied for licensing and distribution to pharmaceutical partners.
  • Cabozantinib Generic version of Cabometyx® (20mg, 40mg, 60mg tablets) for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer, supplied for licensing and distribution to pharmaceutical partners.
  • Eltrombopag Generic version of Revolade®/Promacta® (25/50/75 mg tablets) for thrombocytopenia and severe aplastic anemia, supplied for licensing and distribution to pharmaceutical partners.
  • Enzalutamide

Quantifiable outcome

  • Portfolio of 20+ molecules including top sellers like ibrutinib (Imbruvica®) and palbociclib (Ibrance®)
  • +2 more outcomes

Companies that use onconcept®

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

onconcept® technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

onconcept® partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • BluepharmacoreStrategic or Co-development PartnerBluepharma is a Portuguese pharmaceutical company operating as a CDMO with all capabilities needed to develop medicines from concept through commercial manufacturing. Bluepharma brings EU-GMP approved manufacturing capabilities, global regulatory experience, and the manufacturing facility base for ONConcept. As a founding partner, Bluepharma provides development expertise, regulatory filing capabilities, and the production infrastructure.
  • Helm Pharma (Helm AG)coreStrategic or Co-development PartnerHelm is a family-owned, 120-year-old German pharmaceutical company with strong track record collaborating with international partners on generic pharmaceutical development. Helm brings scientific, regulatory, and quality expertise, experience coordinating different stakeholders, and special expertise in identifying opportunities for difficult and complex molecules. As a founding partner, Helm handles active pharmaceutical ingredient (API) expertise and regulatory coordination.
  • Welding (Welding GmbH & Co. KG)coreStrategic or Co-development PartnerWelding is a German pharmaceutical company based in Hamburg, with history dating back to 1955 involved in API supply. Welding brings expertise in identifying and handling ingredients, connecting API suppliers to finished dosage form manufacturers. The company has excellent reputation for leading projects from start to finish, with experience in markets including India, China, and the US. As a founding partner, Welding provides API sourcing network and project leadership.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

onconcept® competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

onconcept® social profiles

Digital presence

onconcept® compliance and trust

Trust signal

Compliance7 records

onconcept® financial estimates

Financial estimate

Revenue estimate

Valuation estimate

onconcept® leadership team

Management profile

Number of profiles

Profiles4 records

onconcept® funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

onconcept® M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about onconcept®

What does onconcept® do?

ONConcept® is a strategic partnership that develops, manufactures, and licenses generic versions of oncology and other highly potent pharmaceutical products (oral solid dosage forms) for marketing partners worldwide. The partnership operates a €30 million EU-GMP approved manufacturing facility in Portugal and provides integrated CDMO services across the full pharmaceutical value chain, including IP support, API sourcing, FDF development/manufacturing/supply chain, clinical development, and regulatory support for more than 20 molecules.

Is onconcept® a public or private company?

onconcept® is a private company. It is classified as corporate owned and is currently operating.

When was onconcept® founded?

onconcept® was founded in 2019. It employs 501 to 1,000 people.

Where is onconcept® based?

onconcept® is headquartered in Coimbra, Portugal, in the Europe region.

How does onconcept® make money?

Three revenue lines are on record. Pharmaceutical Licensing is the primary driver. The others are contract Development and Manufacturing (CDMO) and product Supply.

Does onconcept® have an API?

No public API is recorded for onconcept®.

What industry is onconcept® in?

onconcept®'s product category is Generic Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales